AKT1 and B-cell chronic lymphocytic leukemia: The phosphorylated PI3K/AKT signaling pathway can be considered a new biomarker of severe clinical outcomes in CLL patients, and the inhibition of those signaling pathways may be a possible treatment action option for these patients.